Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MDCO: Medicines Company -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (16)	2/3/2002 4:36:23 PM
From: SemiBull	Read Replies (1) \| Respond to of 125

The Medicines Company Fourth Quarter and Full Year Financial Results and Conference Call Notice CAMBRIDGE, Mass.--(BW HealthWire)--Feb. 1, 2002--The Medicines Company (Nasdaq: MDCO - news) will be hosting a conference call beginning at 5:00 p.m. Eastern time February 12, 2002 to discuss its fourth quarter and full-year financial results. These results, for the quarter and year ended January 31, 2001, will be released at 4:00 p.m. Eastern time on February 12, 2002. Clive Meanwell, M.D., Ph.D., Executive Chairman, Dave Stack, President and Chief Executive Officer, and Peyton Marshall, Ph.D., Chief Financial Officer, will lead the conference call. To listen to the conference call, please dial 800-472-8325 and request The Medicines Company 2001 Fourth Quarter conference call. If you are calling from outside of the United States, please dial 1-706-679-0816. If you cannot attend the live call, a digital replay will be available through February 26. Please call 800-642-1687 in the U.S. or 1-706-645-9291 internationally and enter passcode 2929840. Additionally, this call is being webcast by CCBN and can be accessed at The Medicines Company's web site (www.themedicinescompany.com). The Medicines Company was founded in 1996 to acquire, develop and commercialize selected pharmaceutical products in late stages of development and approved products. In December 2000, the Company received marketing approval from the U.S. Food and Drug Administration for ANGIOMAX® (bivalirudin) for use as an anticoagulant in combination with aspirin in patients with unstable angina undergoing coronary balloon angioplasty. The Company began selling ANGIOMAX in the United States in January 2001. The Company expects ANGIOMAX to be the cornerstone product of a planned acute hospital franchise. The Company is also developing a second product, CTV-05, a proprietary biotherapeutic agent with a potentially broad range of applications in the treatment of gynecological and reproductive infections. Additional information about the company and its products can be found at www.themedicinescompany.com. This press release contains forward-looking statements that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words, ``believes,'' ``anticipates,'' ``plans,'' ``expects,'' ``intends,'' and similar expressions are intended to identify forward-looking statements. Important factors that could cause actual results to differ materially from the expectations described in these forward-looking statements are set forth under the caption ``Certain Factors that May Affect Future Results'' in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2001 and incorporated herein by reference. These risk factors include risks as to the commercial success of ANGIOMAX; how long the Company will be able to operate on its existing capital resources; whether the Company's products (other than ANGIOMAX for its approved indication) will advance in the clinical trials process, the timing of such clinical trials, whether the clinical trial results will warrant continued product development, whether and when, if at all, the Company's products will receive approval from the U.S. Food and Drug Administration or equivalent regulatory agencies, and for which indications, and, if such products receive approval, whether they will be successfully marketed; the Company's history of net losses; and the Company's dependence on third parties, including manufacturers, suppliers and collaborators. We do not assume any obligation to update any forward-looking statements. -------------------------------------------------------------------------------- Contact: Jill Sawdon Director, Corporate Communications The Medicines Company (617) 225-9099 (ph)